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Abstract
Oral squamous cell carcinoma (OSCC), one of the most common malignancies in the head
and neck region, is graded based on Broder’s classification into well-differentiated,
moderately, and poorly differentiated. Cytokeratin 17 (K17, CK17) is an acid-type I
cytokeratin with a low-molecular weight of 48.1 kDa. Epithelial cell adhesion molecule
(EpCAM) is a hemophilic Ca2+ independent adhesion molecule. This study used an
immunohistochemical technique (IHC) to examine the expression of CK17 and EpCAM
in thirty-two specimens of OSCC (comprising 13 well-, 9 moderately, and 10 poorly
differentiated cases), and 2 specimens of normal oral mucosa, used as control. I was found
that the mean area fraction of CK17 and EpCAM immunopositivity became lower as the
grade increased. A highly statistically significant difference between groups (P-value 
0.001). A significant correlation existed between the level of CK17 and EpCAM in OSCC
(P-value = 0.0000). We concluded that CK17 and EpCAM are associated with malignancy
and differentiation of OSCC. CK17 could have potential as a diagnostic marker of OSCC.
In addition, EpCAM could be a biomarker for prediction of the progression and the
prognosis of OSCC patients. This study used an immunohistochemical technique (IHC) to
examine the expression of EpCAM in thirty-two specimens of OSCC (comprising 13 well, 9 moderately, and 10 poorly differentiated cases), and 2 specimens of normal oral mucosa,
used as control. It was found that the mean area fraction of EpCAM immunopositivity
became lower as the grade worsened. A highly statistically significant difference existed
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between groups (P-value  0.001). We concluded that EpCAM could help to stratify the
different grades of OSCC. In addition, EpCAM could be a biomarker for prediction of
prognosis.
Key words: OSCC, CK17, EpCAM, IHC

Introduction
Oral squamous cell carcinoma (OSCC) is one of the most common malignancies in the
head and neck region, afflicting about 300,000 patients worldwide each year(1). This tumor entity
represents more than 95% of all malignant neoplasms in the oral cavity accounting for about 4%
of all carcinomas in men and 2% in women worldwide, with a varying geographical frequency(2).
OSCC arises by malignant change in oral mucosa(3) and is graded into well-differentiated,
moderately, and poorly differentiated. Well-differentiated SCC closely resembles normal
squamous mucosa whereas moderately differentiated SCC displays nuclear pleomorphism,
mitoses (including atypical forms), and usually less keratinization. In poorly differentiated SCC,
immature cells predominate, with numerous typical and atypical mitoses, minimal keratinization,
and sometimes necrosis(4,5).
Over the last decades, much progress has been made in understanding the molecular
alteration that lead to oncogenic transformation, accompanied by an extensive search for
biomarkers that predict the behavior of cancer(6).
Cytokeratin 17 (K17, CK17), being a component of cytoskeleton protein with a lowmolecular weight of 48.1 kDa and 432 residues, is an acid-type I cytokeratin with an isoelectric
pH of 4.7. The CK17 gene (KRT17) has seven introns and eight exons covering approximately
5.14 Kbp on 17q12-q21(7). In addition, CK17 is expressed at the same time as CK6, with which it
forms heterodimers, although it can also combine with CK5, CK8 and CK16(8). Cytokeratin 17
expression may also change after premalignant and malignant transformations. CK17 protein is
overexpressed in cancerous tissues compared with normal tissues in cervical(9), laryngeal(10),
esophageal(11), and lung carcinomas(12). However, CK17 expression has not been well studied in
OSCC(13). Moreover, a paucity of material is available on a correlation between the expression and
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the differentiation in OSCC(14). The main function of CK17 is involved in the formation and
maintenance of various skin appendages, specifically in determining shape and orientation of hair.
CK17 is also considered as a marker of basal cell differentiation in complex epithelia and
recognizes cervical stem cells(15). Additionally, CK17 regulates the protein synthesis and cell
growth in injured stratified epithelia by binding to a signaling molecule(16).
Epithelial CAM ,an epithelial transmembrane glycoprotein, was independently identified
by many research groups, resulting in a plethora of synonyms (EpCAM/Ep-CAM(17); syn. GA7332(18), TACSTD1(19), KSA(20), EGP40(21), CD326(22), CO-17A(23), MK-1(24), ESA(25), KS1/4(26)),
although recently a unified nomenclature has been proposed with the terms “EpCAM” and
“CD326”(23). EpCAM was encoded by the TACSTD1 gene that was mapped to chromosome 4q
and recently re-mapped to chromosome 2p21(27,28). The gene for EpCAM contains nine exons with
a large extracellular (EpEX), a single transmembrane and a short intracellular (EpICD) domain(27).
EpCAM molecule is a homophilic and Ca2+ independent adhesion molecule that is expressed in a
variety of human epithelial tissues, progenitor and stem cells(22). EpCAM also appears to be
expressed by the great majority of human epithelial malignancies(29,30). It has been proposed as an
oncogenic signaling protein and was associated with development of malignancy in certain types
of tumors(22).

Material and methods
The material of this study consisted of thirty-two formalin-fixed, paraffin-embedded
specimens of oral squamous cell carcinoma, and two cases were used as control. The cases were
collected from the archives of the Pathology Department, National Cancer Institute, Cairo
University. Thirteen cases were diagnosed as well-differentiated OSCC, nine diagnosed as
moderately differentiated OSCC, and ten cases were diagnosed as poorly differentiated OSCC.
For all specimens five micrometer thick sections were prepared and stained with hematoxylin and
eosin (H&E) stain to confirm the diagnosis.
Monoclonal antibodies against CK17 and EpCAM were used. Monoclonal concentrated
antibodies were purchased from Lab Vision Corporation, USA. These antibodies were designed
for the specific localization of antigen in formalin-fixed paraffin-embedded tissue sections. For all
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specimens, four-micrometer thick sections were prepared and mounted on positively charged glass
slides to be immunostained with anti-CK17 antibody and anti-EpCAM antibody.
For each positive section, four microscopic fields showing highest immunopositivity were
selected and photomicrographs were captured at a magnification of 20X. This was performed using
a digital video camera (C5060, Olympus, Japan) which was mounted on a light microscope (BX60,
Olympus, Japan). Images were then transferred to the computer system for analysis. All the steps
for immunohistochemical evaluation were carried out using image analysis software (Image J,
1.47, NIH, USA).
The collected data was tabulated using Microsoft Excel (Microsoft Office 2010). For each
case, the area fraction of immunopositivity for at least four different microscopic fields was
measured. The mean area fraction for each case was then calculated and used for statistical
analysis. Positive cases were included in the statistical analysis, carried on the tabulated data using
the Statistical Package for Social Science (SPSS 15.0) software. The statistical tests performed.
Analysis Of Variance (ANOVA) test and Tukey pair-wise test were used to test the significance
of difference of means between different grades of OSCC. The results were considered significant
when P-value ≤ 0.05.

Results
Immunohistochemical staining with monoclonal antibody against CK17 protein in
different grades of OSCC revealed that the immunopositive reactions were brown in color with
either cytoplasmic or both cytoplasmic and membranous localization. The normal oral mucosa,
used as control, showed negative immunohistochemical expression of CK17 (Figs. 1, 2, 3).
Immunohistochemical staining with monoclonal antibody against EpCAM protein in
different grades of OSCC revealed that the immunopositive reactions were brown in color with
cytoplasmic, membranous, or both cytoplasmic and membranous membranous localization (Figs.
4, 5, 6). The normal oral mucosa, used as control, showed positive immunohistochemical
expression of EpCAM. This immunoreactivity was seen in the cytoplasm and/or the cell membrane
in all epithelial cells except basal and para-basal cells.

4

Fig. 1: A photomicrograph of well-differentiated OSCC showing cytoplasmic immunopositivity
of the neoplastic cells in cell nests and keratin pearls showing faint immunopositivity (AntiCK17. Original magnification x 20).

Fig. 2: A photomicrograph of moderately differentiated OSCC showing cytoplasmic
immunopositivity of the whole cell nests (Anti-CK17. Original magnification x 20).

5

Fig. 3: A photomicrograph of poorly differentiated OSCC showing cytoplasmic
immunopositivity of the neoplastic cells within sheets, strands, and some individual neoplastic
cells . Some neoplastic cells showed immunonegativity (Anti-CK17. Original magnification x
20).

Fig. 4: A photomicrograph of well-differentiated OSCC showing cytoplasmic and few
membranous immunopositivity of the neoplastic cells within cell nests (Anti-EpCAM. Original
magnification x 20).
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Fig. 5: A photomicrograph of moderately differentiated OSCC showing membranous and
cytoplasmic immunopositivity of the neoplastic cells in cell nests (Anti-EpCAM. Original
magnification x 20).

Fig. 6: A photomicrograph of poorly differentiated OSCC showing cytoplasmic and
membranous immunopositivity of neoplastic cells within tumor nests, sheets, and individual
scattered tumor cells. Some neoplastic cells showed immunonegativity (Anti-EpCAM. Original
magnification x 20).

7

The mean area fraction of CK17 and EpCAM immunopositivity became lower as the grade
worsened [i.e. from well-differentiated to poorly differentiated OSCC] as shown in (Table 1) and
(Fig. 7). When comparing the different grades of OSCC using ANOVA test followed by Tukey
test, there were differences in means of area fractions between groups. Tukey test demonstrated
that

there

was

a

very

highly

statistically

significant

difference

between

groups

(P-value  0.001) as shown in (Table 2). Pearson’s correlation analysis revealed a significant
strong direct positive linear correlation existed between the level of CK17 and EpCAM in OSCC
(R-value = 0.9131) which was found to be statistically significant (P-value = 0.0000). Fig. 8
illustrates a scatter plot showing correlation and regression analysis for CK17 vs. EpCAM in
OSCC.

Fig. 7: Box-plot diagram for means of mean area fraction of CK17 and EpCAM. The horizontal line within
each box indicates the median. The top edge of each box represents the 75th percentile; the bottom edge
represents the 25th percentile. The range is shown as a vertical line.
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Table 1: Descriptive statistics for CK17 and EpCAM immunopositivity in different grades
of OSCC.

Mean
Standard Deviation
Valid N

Well Differentiated
CK17
EpCAM
30.49
16.05
3.36
3.37
11
12

Moderately
Differentiated
CK17
EpCAM
11.21
5.86
1.66
1.33
9
8

Poorly
Differentiated
CK17
EpCAM
4.71
2.23
1.39
1.03
6
10

Table 2: Tukey pair-wise test for CK17 and EpCAM.
Tukey multiple comparisons of means
P-Value
CK17
EpCAM
Well-diff-mod diff
Well-diff-poorly diff
mod diff-poorly diff

0.00000
0.00000
0.00016

0.0000
0.0000
0.0076

Fig. 8: Pearson’s correlation of CK17 with EpCAM showing the trend line and least square lines (dotted).
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Discussion
This study was conducted in order to evaluate the immunohistochemical expression pattern
of an intermediate filament of the cytoskeleton CK17, and a cell adhesion molecule; EpCAM in
different grades of OSCC, as well as to investigate the possible relationship that might exist
between the expressions of these two markers in OSCC.
In the present study, the normal oral mucosa, used as control, showed negative
immunohistochemical expression of CK17. This is consistent with the finding by
Kitamura et al.(14) and Noguchi et al.(31) that there were no positiviteis for CK17 in normal oral
epithelium.
The results of the present study showed overexpression or even de novo expression of
CK17 in oral squamous cancerous tissue compared to normal epithelium and adjacent nonmalignant epithelium. This finding strongly suggested that the overexpression of CK17 could be
associated with malignant transformation. This was found to be consistent with the results of many
studies, such as that of Moll et al.(32) who stated that as most normal stratified squamous epithelia
lack CK17, its presence in the corresponding tumors may be regarded as neo-expression during
tumorigenesis. Also, Kitamura et al.(14), Wei et al.(33), and Noguchi et al.(31) who observed
overexpression of CK17 in a human oral cancer tissue compared to normal epithelium, adjacent
non-malignant epithelium, and dysplastic epithelium, respectively. Linear with these data, CK17
has been reported to demonstrate higher expression in cancerous tissues compared to normal
tissues in cervical(9), laryngeal(10), esophageal(11), and Lung SCCs(12),
An overview on the immunohistochemical results of the present study showed that the
mean area fraction of the expression of CK17 became less pronounced as the grade worsened [i.e.
down-regulated from well-differentiated, through moderately differentiated, to poorly
differentiated OSCC]. These results were found to be in harmony with the results of
Toyoshima et al.(13) and Kitamura et al.(14) who stated that there was a significant expression of
CK17 in well-differentiated OSCC compared to moderately and poorly differentiated OSCC.
Additionally, Ikeda et al.(9) demonstrated that the immunostaining of CK17 was significantly
correlated with increasing grade of cervical intraepithelial neoplasia and SCC in cervix. Variance
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in CK17 expression between the different histopathological grades of OSCC in the present study
might be explained by the argument of Poschmann et al.(34) who speculated that during the cell
transition from bronchial epithelium to moderately differentiated squamous cell lung cancer, the
expression of CK17 is initially induced and declines with further dedifferentiation of the tumor
cells. Therefore, CK17 protein expression pattern might help to discriminate between tumor grades
in a significant and objective manner.
In the present study, the normal oral mucosa, used as control, showed positive
immunohistochemical expression of EpCAM. This immunopostivity was cytoplasmic and/or
membranous found in all epithelial cells except basal and para-basal cells. These results were
found to be consistent with the finding by Hwang et al.(35) who stated that normal oral epithelial
cells showed membranous and/or cytoplasmic EpCAM expression in all epithelial cells except
some basal and para-basal cells.
The results of the present study showed increased EpCAM expression in oral squamous
cancerous tissue compared to those in normal epithelium and adjacent non-malignant epithelium.
This is consistent with the results of Laimer et al.(36) and Gupta and Rao(37) who found that in
OSCC the EpCAM protein appears to be de nove expressed or overexpressed. Actually,
overexpression of EpCAM has been demonstrated in various human carcinomas, including head
and neck(38), breast(39), cervical(40), esophageal(41), gastric, colorectal, prostatic, and lung
carcinomas(42). These findings might indicate that increases in EpCAM expression is an early step
in the malignant transformation of oral epithelium and could be involved in the initiation of OSCC,
and thus, could be used as a marker for diagnostic purposes(43). Moreover, it is tempting to suggest
that the patients presenting EpCAM overexpression would qualify for EpCAM directed
immunotherapeutic approaches(36).
An overview on the immunohistochemical results of the present study, regarding the
EpCAM overexpression, showed that the mean area fraction of the expression of EpCAM became
less pronounced as the grade worsened [i.e. down-regulated from well-differentiated, through
moderately differentiated, to poorly differentiated OSCC]. This might indicate EpCAM as an
interesting candidate biomarker that could help to stratify OSCC tumor grades. Additionally,
EpCAM can be a biomarker for prediction of the progression and the prognosis of OSCC patients.
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In contrast to its promoting role regarding tumor formation, EpCAM is also described as a
tumor suppressive protein. EpCAM was first proposed to function as a cell adhesion molecule,
since EpCAM is able to mediate homophilic adhesive interactions(17). The extracellular region of
EpCAM contains two epidermal growth factor (EGF)-like domains which are involved in both
reciprocal interactions between EpCAM molecules on adjacent cells and lateral interactions
between EpCAM molecules(44). These interactions thereby prevent cell scattering. Due to these
adhesive properties, EpCAM is likely to play a role in inhibition of invasion(17). Indeed, loss of
EpCAM contributed to increased migratory potential(45) and EpCAM expression on metastases
was lower compared with primary tumors(46).
Pearson’s correlation showed that there was a strong significant positive correlation
between level of CK17 and EpCAM expression (R-value = 0.9131). This correlation was proven
to be statistically significant (P-value = 0.0000). This could be explained by the ability of CK17
to regulate cell growth and synthesize proteins resulting in epithelial proliferation and tumor
progression via activation of signaling pathways, and EpCAM different biological functions
including EpCAM mediated homotypic cell-cell adhesion, promoting cell motility, proliferation,
survival, carcinogenesis, and metastasis formation. So these two markers could function in a
synergistic way to facilitate the neoplastic transformation and tumor progression in the different
grades of OSCC.

Conclusion


CK17 and EpCAM are associated with malignancy and differentiation of OSCC.



CK17 could have potential as a diagnostic marker of OSCC. In addition, CK17 could be a
precise candidate for early diagnosis of well-differentiated cases.



EpCAM could be a biomarker for prediction of the progression and the prognosis of OSCC
patients.



A very strong correlation exists between the level of CK17 and EpCAM in OSCC.
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